| Dr Jose A Rodriguez, | |
|
Carr 140 Urb Reparto Julio, Vaclle Vega A4, Barceloneta, PR 00617-0061 | |
| (787) 557-3730 | |
| Not Available |
| Full Name | Dr Jose A Rodriguez |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Location | Carr 140 Urb Reparto Julio, Barceloneta, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760150064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jose A Rodriguez, Carretera 2 Cruce Davila, Urb Reparto Julio, Barceloneta, PR 00617 Ph: (787) 557-3730 | Dr Jose A Rodriguez, Carr 140 Urb Reparto Julio, Vaclle Vega A4, Barceloneta, PR 00617-0061 Ph: (787) 557-3730 |
News Archive
Pregnancy is the biggest killer of teenage girls worldwide, with one million girls annually dying, being injured, or contracting a disease because of pregnancy or childbirth, according to a report (.pdf) released Tuesday by Save the Children, the Daily Mail reports.
Today, Lung Cancer Alliance highlighted a study, carried out by Ipsos MORI on behalf of The Global Lung Cancer Coalition. The study finds lung cancer patients are likely to suffer significant stigma due to the disease's link to smoking.
In the U.S., someone suffers a heart attack every 34 seconds - their heart is starved of oxygen and suffers irreparable damage. Engineering new heart tissue in the laboratory that could eventually be implanted into patients could help, and scientists are reporting a promising approach tested with rat cells.
Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".
An advisory panel from the United States Food and Drug Administration (FDA) has recommended the approval of a novel epilepsy drug that is made up of ingredients from marijuana. The agency normally follows the recommendations of the advisory panels regarding approvals and rejections of applications of new drugs. The recommendation statement came yesterday (19th April 2018).
› Verified 3 days ago
Josean X Rosario, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 111 Bo Cruce Davila, Barceloneta, PR 00617 Phone: 787-346-0207 |